Rigel Pharmaceuticals Inc. (RIGL)

3.78
0.18 5.00
NASDAQ : Health Technology
Prev Close 3.60
Open 3.62
Day Low/High 3.60 / 3.83
52 Wk Low/High 2.14 / 4.71
Volume 1.94M
Avg Volume 2.42M
Exchange NASDAQ
Shares Outstanding 147.37M
Market Cap 565.90M
EPS -0.60
P/E Ratio 384.00
Div & Yield N.A. (N.A)

Latest News

Three Biotech Names to Consider

Three Biotech Names to Consider

A look at three names to consider in the biotech and biopharma space.

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 50.6% Annualized Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 50.6% Annualized Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.89/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $2.50 strike, which has a bid at the time of this writing of 35 cents.

Rigel Announces Departure Of Chief Financial Officer

Rigel Announces Departure Of Chief Financial Officer

Launches Search for Chief Financial Officer with Commercial-Stage Expertise

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 20% Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 20% Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.87/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $2.50 strike, which has a bid at the time of this writing of 50 cents.

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers

Dimension Therapeutics said Oct. 3 it has agreed to sell to Ultragenyx Pharmaceutical for $6 a share in cash or about $151M.

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

The South San Francisco, Calif.-based firm said the U.S. Food and Drug Administration indicated that it does not plan to conduct an Oncology Drugs Advisory Committee meeting to discuss Rigel's new drug application for fostamatinib in chronic or persistent immune thrombocytopenia.

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 30.6% Annualized Using Options

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 30.6% Annualized Using Options

Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $2.85/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2018 put at the $2.50 strike, which has a bid at the time of this writing of 55 cents.

Biotech Movers: Clovis, Seattle Genetics, Rigel

Biotech Movers: Clovis, Seattle Genetics, Rigel

Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

Arena Pharmaceuticals, Rigel Pharmaceuticals and Cytokinetics were among the biotech stock movers in premarket trading on Tuesday.

Immunomedics, Mylan Lead Biotech Movers

Immunomedics, Mylan Lead Biotech Movers

Investors weren't completely distracted by the Affordable Care Act debate.

Commit To Purchase Rigel Pharmaceuticals At $2.50, Earn 18% Using Options

Investors eyeing a purchase of Rigel Pharmaceuticals Inc stock, but cautious about paying the going market price of $2.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $2.50 strike, which has a bid at the time of this writing of 45 cents.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

TheStreet Quant Rating: D (Sell)